Therapeutic approaches for intraocular lymphoma
| Therapy . | Efficacy . | Toxicity . | Reference . |
|---|---|---|---|
| Ocular XRT (30-40Gy) Wash U Protocol = 35 Gy | Rare local recurrence 60-95% RR; no impact on OS | Cataracts, dry eyes, retinopathy (mild) | Berenbom et al, 2007112 |
| HD-MTX | ∼50% sustained response, poor vitreous penetration | Mild | Batchelor et al, 2003115 |
| HD-MTX + Binocular XRT (± overlap) | 100% CR | Cataracts, dry eyes, retinopathy | Stefanovic et al, 2010117 |
| Intensive chemo (EA) + ASCT (TBC) | >50% patients respond to EA; 6/10 CR | Neurologic toxicity, hemorrhage, VOD | Soussain et al, 200179 |
| Intravitreal rituximab (1 mg) or MTX (200 mcg) in 0.1 mL | Requires >6 injections to achieve CR; investigational | Conjunctival keratopathy, cataracts, optic atrophy, endophthalmitis | Itty and Pulido, 2009114 ; Kim et al, 2006111 |
| Therapy . | Efficacy . | Toxicity . | Reference . |
|---|---|---|---|
| Ocular XRT (30-40Gy) Wash U Protocol = 35 Gy | Rare local recurrence 60-95% RR; no impact on OS | Cataracts, dry eyes, retinopathy (mild) | Berenbom et al, 2007112 |
| HD-MTX | ∼50% sustained response, poor vitreous penetration | Mild | Batchelor et al, 2003115 |
| HD-MTX + Binocular XRT (± overlap) | 100% CR | Cataracts, dry eyes, retinopathy | Stefanovic et al, 2010117 |
| Intensive chemo (EA) + ASCT (TBC) | >50% patients respond to EA; 6/10 CR | Neurologic toxicity, hemorrhage, VOD | Soussain et al, 200179 |
| Intravitreal rituximab (1 mg) or MTX (200 mcg) in 0.1 mL | Requires >6 injections to achieve CR; investigational | Conjunctival keratopathy, cataracts, optic atrophy, endophthalmitis | Itty and Pulido, 2009114 ; Kim et al, 2006111 |
TBC, thiotepa, busulfan, cyclophosphamide; VOD, venoocclusive disease.